Skip to main content
Clinical Trials/NCT05177978
NCT05177978
Completed
Not Applicable

The Chronic Cognitive Effects of 6- and 12-weeks Administration of a Food Supplement Containing Phosphatidylserine: A Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Children Aged 8 to 12 Years

Northumbria University1 site in 1 country208 target enrollmentNovember 2, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cognitive Change
Sponsor
Northumbria University
Enrollment
208
Locations
1
Primary Endpoint
COMPASS global performance measures
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to assess the cognitive effects (attention, learning, and memory) of 6 and 12 weeks administration of a supplement containing phosphatidylserine in comparison to a placebo in healthy children aged 8 to 12 years old. The study will utilize Rey Auditory Verbal Learning Test (RAVLT) and Computerised Mental Performance Assessment System (COMPASS, Northumbria University) for a broad assessment of cognitive function/learning, and actigraphy to monitor sleep.

Registry
clinicaltrials.gov
Start Date
November 2, 2020
End Date
August 14, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Philippa Jackson

Principal Investigator

Northumbria University

Eligibility Criteria

Inclusion Criteria

  • Participants must be in good health as reported by themselves and their parent/guardian.
  • Healthy children aged 8 to 12 years and enrolled in school years 4 to 7 at the time of giving consent
  • Have been speaking English at school since reception
  • Willingness of the children and parents to give their written informed consent, according to GCP and local regulations and being able to participate in all scheduled visits, intervention plans, tests and other trial procedures
  • Children with a normal sex and age-related BMI according to the local NHS guidelines (3rd to 90th percentiles)

Exclusion Criteria

  • Relevant allergy or known hypersensitivity to one of the ingredients contained in the investigational drug.
  • Are currently taking any illicit, herbal or recreational drugs including alcohol and tobacco.
  • Taking any prescribed or OTC medication against chronic or non- chronic illnesses.
  • Have used dietary supplements within the last 4 weeks
  • Are diagnosed with ADHD, dyslexia or any neurodevelopmental disorder or learning difficulty.
  • Suffer from visual (including colour blindness) or hearing impairment (that may impact task performance in the opinion of the PI.
  • Have any serious illness, cognitive impairment or medical disorder that may confound with study results or interfere with compliance.
  • Have any other active or unstable medical condition, that, in the opinion of the PI, may adversely affect the participant's ability to complete the study
  • Are experiencing exceptional social/family stressors.
  • Consume more than one portion (\>100g) per week of the following dietary sources high in phosphatidylserine: Oily fish such as salmon, mackerel, herring, tuna and eel. Animal internal organs such as liver, kidney, brain and heart. Note: Information on continued adherence to this criteria will be captured within treatment diary. If a child continuously consumes more than one portion per week of PS rich food the sponsor will be informed on a case by case basis. If deemed to be significant, they will be excluded, (but allowed to continue the study to the end (day 84)) and will be replaced.

Outcomes

Primary Outcomes

COMPASS global performance measures

Time Frame: Following 12 weeks of intervention

Speed of performance, and accuracy of performance measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University)

Cognitive domain factor score

Time Frame: Following 12 weeks of intervention

Speed of attention, accuracy of attention, speed of memory, accuracy of working memory, and accuracy of episodic memory measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University)

Location Learning score

Time Frame: Following 12 weeks of intervention

Learning index, displacement score, and delayed recall score, measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University)

Rey Auditory Verbal Learning Test (RAVLT)

Time Frame: Following 12 weeks of intervention

Learning score, Immediate recall, delayed recall, and delayed recognition measured by the Rey Auditory Verbal Learning Test

Secondary Outcomes

  • Parent Visual Analogue Scales (VAS)(Following 6 and 12 weeks of intervention)
  • Rey Auditory Verbal Learning Test (RAVLT)(Following 6 weeks of intervention)
  • Children's Sleep Habits Questionnaire (CSHQ)(Following 6 and 12 weeks of intervention)
  • Sleep measures(Following 12 weeks of intervention)
  • Cognitive domain factor score(Following 6 weeks of intervention)
  • Individual cognitive task score(Following 6 and 12 weeks of intervention)
  • COMPASS global performance measures(Following 6 weeks of intervention)
  • Children's Sleep self-report (SSR) questionnaire(Following 6 and 12 weeks of intervention)
  • Location Learning score(Following 6 weeks of intervention)
  • Child mood Visual Analogue Scales (VAS)(Following 6 and 12 weeks of intervention)

Study Sites (1)

Loading locations...

Similar Trials